This is a Phase 1/2 trial registry record with no results reported; it describes a planned study of an investigational agent in early development stages.
Reported
Estimated enrollment60
Study phasePhase 1, Phase 2
Primary endpoint (Dose Escalation…Number of Dose Limiting Toxicities (DLTs) f…